Abstract | OBJECTIVE: SUBJECTS AND METHODS: This was a real-world single-center retrospective cohort study. In total 158 patients with pathologically confirmed intermediate-risk NMIBC were included, who were divided into 4 subgroups based on the number of instillations given. We used Cox regression analysis and survival analysis chart to explore the 3-yr recurrence outcomes of tumor.The optimal duration was determined by receive operating characteristic curve (ROC). RESULTS: The median follow-up was 5.2 years. Compared with instillation for 1-2 months, the Hazard Ratios(HR) values of instillation for less than 1 month, maintenance instillation for 3-6 months and > 6 months were 3.57、1.57 and 0.22(95% CI 1.27-12.41;0.26-9.28;0.07-0.80, P = 0.03;0.62;0.02, respectively). We found a significant improvement in 3-yr relapse-free survival in intermediate-risk NMIBC patients who maintained intravesical instillation chemotherapy for longer than 6 months, and the best benefit was achieved with 10.5 months of maintenance chemotherapy by ROC. CONCLUSIONS: In our scheme, the optimal duration of intravesical instillation with pirrubicin is 10.5 months. This new understanding provides valuable experience for the precise medical treatment model of intermediate-risk NMIBC.
|
Authors | Jian-Xin Chen, Wen-Ting Huang, Qing-Yun Zhang, Cheng-En Deng, Jue-Ling Wei, Yuan-Liang Xie, Rui Lin, Guan-Zheng Feng, Guang-Lin Yang, Jun Long, Hao-Yuan Lu, Zeng-Nan Mo |
Journal | BMC cancer
(BMC Cancer)
Vol. 23
Issue 1
Pg. 1018
(Oct 23 2023)
ISSN: 1471-2407 [Electronic] England |
PMID | 37872516
(Publication Type: Journal Article)
|
Copyright | © 2023. BioMed Central Ltd., part of Springer Nature. |
Chemical References |
|
Topics |
- Humans
- Administration, Intravesical
- Maintenance Chemotherapy
- Retrospective Studies
- Non-Muscle Invasive Bladder Neoplasms
- Neoplasm Recurrence, Local
(drug therapy, pathology)
- Urinary Bladder Neoplasms
(pathology)
- BCG Vaccine
(therapeutic use)
- Neoplasm Invasiveness
|